Mantle Cell Lymphoma Stage III
Mantle cell lymphoma stage III is a rare and aggressive form of blood cancer that affects lymph nodes on both sides of the diaphragm. While the diagnosis can be challenging, understanding this condition and the available treatment options can help patients and their families navigate the journey ahead.
Table of contents
- What is mantle cell lymphoma?
- Understanding stage III disease
- Signs and symptoms
- How is it diagnosed?
- Treatment approaches
- Outlook and survival
What is mantle cell lymphoma?
Mantle cell lymphoma is a rare type of blood cancer that develops when white blood cells called B lymphocytes (B cells) grow out of control[1]. B cells are part of your immune system and normally help fight infections by making antibodies. This cancer is called “mantle cell” lymphoma because the abnormal B cells typically develop in a part of the lymph nodes called the mantle zone[1].
Mantle cell lymphoma is quite rare, making up only about 5 to 6 percent of all non-Hodgkin lymphomas[2][8]. It affects approximately 1 in 200,000 people[3]. The disease most commonly affects men over 60 years old, with men being diagnosed about three times more often than women[2][4].
This type of lymphoma is unusual because it often has features of both fast-growing and slow-growing cancers[1]. In most cases, mantle cell lymphoma begins as a slow-growing cancer that later grows rapidly and spreads throughout the lymphatic system[3]. The cancer is characterized by a specific genetic change where pieces of chromosomes 11 and 14 swap places, causing cells to produce too much of a protein called cyclin D1, which makes cells grow uncontrollably[4][7].
Understanding stage III disease
When doctors diagnose mantle cell lymphoma, they determine the stage of the disease to understand how far it has spread. This information helps guide treatment decisions. Stage III mantle cell lymphoma means the cancer has spread to lymph nodes on both sides of the diaphragm (the muscle that separates the chest from the abdomen), or to lymph nodes above the diaphragm and the spleen[2][9].
Most people with mantle cell lymphoma are diagnosed at an advanced stage, with stage III or IV disease[13]. By the time of diagnosis, the disease has often spread to multiple areas, including the lymph nodes, bone marrow, spleen, and sometimes the gastrointestinal tract[4][8].
Signs and symptoms
Many people with mantle cell lymphoma have no obvious symptoms at first, which can delay diagnosis[2]. The symptoms can vary from person to person and may resemble ordinary illnesses, which is why they don’t always appear to be cancer-related[3].
The most common sign of mantle cell lymphoma is swollen lymph nodes in the neck, underarm, or groin[3][8]. These may appear as painless lumps under the skin. Other common symptoms include:
- Fatigue or persistent tiredness[2][3]
- Unexplained weight loss[2][8]
- Night sweats[2][3]
- Fever[2][3]
- Loss of appetite[3][8]
In advanced stages, when the cancer has spread to the digestive system, symptoms may include abdominal pain or bloating, nausea, and changes in bowel habits[2][3]. Some people may also experience headaches, bruising, weakness, or indigestion[3].
How is it diagnosed?
Healthcare providers often suspect mantle cell lymphoma after routine blood work shows an abnormally high number of lymphocytes[3]. Diagnosis typically begins with a physical examination to check for swollen lymph nodes in the neck, underarms, and groin, as well as checking for a swollen spleen or liver[7].
Several tests are used to confirm the diagnosis and determine how far the cancer has spread:
Blood tests can sometimes show if lymphoma cells are present in the blood. They also measure levels of certain proteins, such as lactate dehydrogenase (LDH), which is often higher in people with lymphoma[7][8].
Lymph node biopsy is one of the most important tests. A healthcare provider removes all or part of a lymph node, and the tissue sample is sent to a laboratory for testing[7]. In the lab, specialists look for cancer cells and perform special tests to identify the specific type of lymphoma. More than 90 percent of mantle cell lymphoma cases show an overproduction of cyclin D1 protein, which is a very sensitive diagnostic marker[8].
Bone marrow biopsy involves taking samples from the bone marrow, typically from the hip bone, to check if cancer cells have spread there[7]. This procedure helps determine the extent of the disease.
Imaging tests such as CT scans and PET scans create pictures of the body to show the location and extent of the lymphoma[7][3]. Depending on the situation, doctors may also use colonoscopy or endoscopy to check if the cancer has spread to the digestive system[3].
Treatment approaches
Treatment for mantle cell lymphoma stage III depends on several factors, including the patient’s age, overall health, and how aggressive the disease is[2]. Most patients with stage III disease will require treatment[14].
Chemotherapy and immunotherapy are the most common initial treatments. Patients typically receive a combination of drugs that includes rituximab, a medication that helps the immune system recognize and kill cancer cells[2][9]. These drugs travel through the bloodstream to kill cancer cells wherever they are found[2]. Common chemotherapy combinations include R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) and Hyper-CVAD (cyclophosphamide, vincristine, doxorubicin, dexamethasone alternating with high-dose methotrexate and cytarabine)[14].
Targeted therapies are newer medications that specifically attack cancer cells. BTK inhibitors such as ibrutinib and zanubrutinib have shown promising results in treating mantle cell lymphoma[14]. These drugs work by blocking specific proteins that cancer cells need to grow and survive.
Stem cell transplantation may be recommended for younger, healthier patients after initial chemotherapy. This involves collecting the patient’s own stem cells, giving high-dose chemotherapy to destroy cancer cells, and then returning the stem cells to help the body produce new, healthy blood cells[2][14]. Stem cell transplant performed during first remission has been shown to be most effective[12].
Radiation therapy uses high-energy X-rays to kill cancer cells in specific areas of the body, usually lymph nodes[2][9]. It is often used when cancer doesn’t respond well to chemotherapy.
CAR T-cell therapy is an advanced immunotherapy where doctors collect the patient’s T cells (immune cells), modify them in a laboratory to better fight the lymphoma, and return them to the patient’s body[2][9]. This therapy is often used if the cancer returns after other treatments.
For older or less healthy patients, less intensive chemotherapy followed by maintenance therapy with rituximab alone may be recommended[14]. Maintenance therapy involves giving rituximab at regular intervals after initial treatment to help prolong remission[13].
Outlook and survival
Mantle cell lymphoma is highly responsive to treatment, although it is not curable in most cases[13]. People with this condition often experience cycles of remission (when symptoms go away) and relapse (when symptoms return)[3]. However, treatment can significantly lengthen the time spent in remission and manage symptoms effectively.
Survival rates have improved significantly in recent years due to new treatment options. Studies show that the median overall survival for mantle cell lymphoma ranges from 6 to nearly 10 years, with some research suggesting up to 11 years for patients diagnosed after 2000[24]. The five-year relative survival rate is roughly 75 percent, meaning that 75 out of 100 people with mantle cell lymphoma are alive five years after diagnosis[24].
Several factors can affect prognosis, including the patient’s age, overall health, disease stage, and specific characteristics of the cancer cells[4]. Patients with higher levels of certain blood proteins like LDH or beta-2 microglobulin may have more aggressive disease[8].
It’s important to remember that statistics represent averages across large groups of people and may not reflect an individual’s specific situation. Treatment advances continue to improve outcomes, and many patients with mantle cell lymphoma live for many years with good quality of life[12][24].
